News and Press Releases
Touchlight Partners with SVF Vaccines to Advance Innovative Hepatitis B/D Vaccine to Clinic
9 April 2026 -- London, UK -- Touchlight, a leading biotechnology company specialising in cell-free DNA manufacturing, is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 9, 2026
Samsung Biologics completes acquisition of GSK’s manufacturing facility in Rockville, Maryland
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support Plans...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 31, 2026
University of Colorado Grants License to Cirena for RNA-Synthesis Technology
Foundational synthesis technology enables scalable modified 100-400nt RNA constructs, speeding design cycles and improving genome-editing precision 10 March 2026 -- Colorado, US -- Cirena has secured a license to the...
Category: Biotechnology, Drug Discovery, Manufacturing and Packing, Other
Posted: March 10, 2026
Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases
Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
6 October 2025 -- London, UK -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements...
Category: Logistics, Other, Pharmaceutical
Posted: October 6, 2025
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma
Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed UK...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis 10 December 2024 -- London, UK -- Relation, an industry leader in deploying computation and...
Category: Drug Discovery, Other, Pharmaceutical
Posted: December 10, 2024
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...
Category: BioManufacturing
Posted: September 9, 2024
Touchlight to Supply GMP dbDNA to Support University of Nottingham’s Clinical Study for a Next-Generation Vaccine for Zika Virus
21 August 2024 -- Hampton, UK -- Touchlight, an innovation-driven contract development and manufacturing organization (CDMO) specializing in enzymatic DNA production, is proud to announce the clinical supply of its proprietary...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: August 21, 2024
Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Agreement enables GSK access to enzymatic production technology for rapid GMP production of DNA template for mRNA vaccine manufacturing 23 July 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 23, 2024
Touchlight and LenioBio Collaborate to Accelerate Development of Protein Therapeutics for Pandemic Response
Touchlight to participate in LenioBio’s recently announced grant from CEPI 2 July 2024 -- Hampton, UK, and Düsseldorf, Germany -- LenioBio, a biotech company pioneering cell-free protein production, and Touchlight,...
Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: July 2, 2024
GSK’s Omjjara▼ (momelotinib) is accepted for use within NHS Scotland, in line with its licence, for eligible adult myelofibrosis patients with moderate to severe anaemia
Clinicians in Scotland will now have the option to use momelotinib for the treatment of disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia Momelotinib is...
Category: Other, Pharmaceutical
Posted: June 10, 2024
GSK’s Jemperli▼ (dostarlimab) is accepted for use within NHS Scotland, in line with its licence, in eligible endometrial cancer patients in first line setting
Clinicians in Scotland will now be able to use dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced...
Category: Pharmaceutical
Posted: April 8, 2024
University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study
The UK’s Medical Research Council is funding a 10-patient phase 1 study to deliver rapid personalised treatment for lung cancer patients 3 April 2024 -- Hampton, UK -- Touchlight, a...
Category: Biotechnology, Clinical Trials
Posted: April 3, 2024
